Sadiq Afia, Chow James C L
Department of Medical Physics, Toronto Metropolitan University, Toronto, ON M5B 2K3, Canada.
Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5G 1X6, Canada.
Nanomaterials (Basel). 2022 Aug 29;12(17):2991. doi: 10.3390/nano12172991.
In nanoparticle (NP)-enhanced orthovoltage radiotherapy, bone scatter affected dose enhancement at the skin lesion in areas such as the forehead, chest wall, and knee. Since each of these treatment sites have a bone, such as the frontal bone, rib, or patella, underneath the skin lesion and this bone is not considered in dose delivery calculations, uncertainty arises in the evaluation of dose enhancement with the addition of NPs in radiotherapy. To investigate the impact of neglecting the effect of bone scatter, Monte Carlo simulations based on heterogeneous phantoms were carried out to determine and compare the dose enhancement ratio (DER), when a bone was and was not present underneath the skin lesion. For skin lesions with added NPs, Monte Carlo simulations were used to calculate the DER values using different elemental NPs (gold, platinum, silver, iodine, as well as iron oxide), in varying NP concentrations (3−40 mg/mL), at two different photon beam energies (105 and 220 kVp). It was found that DER values at the skin lesion increased with the presence of bone when there was a higher atomic number of NPs, a higher NP concentration, and a lower photon beam energy. When comparing DER values with and without bone, using the same NP elements, NP concentration, and beam energy, differences were found in the range 0.04−3.55%, and a higher difference was found when the NP concentration increased. By considering the uncertainty in the DER calculation, the effect of bone scatter became significant to the dose enhancement (>2%) when the NP concentration was higher than 18 mg/mL. This resulted in an underestimation of dose enhancement at the skin lesion, when the bone underneath the tumour was neglected during orthovoltage radiotherapy.
在纳米颗粒(NP)增强的正交电压放射治疗中,骨散射会影响前额、胸壁和膝盖等部位皮肤病变处的剂量增强。由于这些治疗部位的每一处在皮肤病变下方都有一块骨头,如额骨、肋骨或髌骨,而在剂量传递计算中未考虑这块骨头,因此在放射治疗中添加NP时,剂量增强评估会出现不确定性。为了研究忽略骨散射影响的后果,基于非均匀体模进行了蒙特卡罗模拟,以确定并比较皮肤病变下方有骨头和没有骨头时的剂量增强率(DER)。对于添加了NP的皮肤病变,使用蒙特卡罗模拟来计算DER值,使用不同的元素NP(金、铂、银、碘以及氧化铁),NP浓度范围为3−40mg/mL,光子束能量为两种不同值(105和220kVp)。结果发现,当NP的原子序数较高、NP浓度较高且光子束能量较低时,皮肤病变处的DER值会随着骨头的存在而增加。当使用相同的NP元素、NP浓度和束能量比较有骨头和没有骨头时的DER值时,发现差异在0.04−3.55%范围内,且当NP浓度增加时差异更大。考虑到DER计算中的不确定性,当NP浓度高于18mg/mL时,骨散射对剂量增强的影响变得显著(>2%)。这导致在正交电压放射治疗期间忽略肿瘤下方的骨头时,会低估皮肤病变处的剂量增强。